Advantan Cream For Dark Marks
Free shipping on orders over $50!
- Satisfaction Guaranteed
- No Hassle Refunds
- Secure Payments
The Advantan Cream For Dark Marks is a cream that will help to lighten the skin and make it look fairer. It is used by women who want to get rid of dark spots on their skin. The cream can also be used in order to reduce the size of the dark spots and also prevent new ones from appearing.
Advantan Cream is a skin lightener that helps fade away dark marks. It’s not just a cream, it’s a treatment!
Advantan Cream is designed to treat the underlying cause of your dark marks. By doing so, you can get rid of your dark spots for good.
Many people think that using a cream alone will help them get rid of their dark marks, but this isn’t always the case. In fact, many creams can have some negative side effects if you aren’t using them properly or if they don’t work for your skin type. That’s why Advantan Cream is such an amazing product—it works on all skin types and has no negative side effects!
Advantan Cream For Dark Marks
Advantan cream is an effective home remedy for dark marks on the skin. It contains kojic acid, which helps lighten the skin tone and reduce the appearance of scars or spots. It works by inhibiting tyrosinase, an enzyme that creates melanin, a pigment that gives your skin its color.
This cream is also useful for reducing acne scars and dark spots on your face. It can be used on all skin types, including sensitive skin.
What Advantan® is used for
The active ingredient in Advantan® belongs to the group of medicines called corticosteroids. The corticosteroid in Advantan® is suitable to put on the skin. It is therefore called a topical corticosteroid, which is sometimes shortened to topical steroid.
When Advantan® is put on the skin, it relieves the redness, swelling, itching and irritation of the skin in eczema and psoriasis.
Advantan® preparations are available only with a doctor’s prescription.
Advantan® is made up as four different preparations. Each has a distinct look and feel. They are:
- fatty ointment
- cream and
Pharmacology: Pharmacodynamics: After topical application, Methylprednisolone aceponate (Advantan) cream, ointment and fatty ointment suppress inflammatory and allergic skin reactions as well as reactions associated with hyperproliferation, leading to regression of the objective symptoms (erythema, edema, weeping) and the subjective complaints (itching, smarting, pain).
It is known that methylprednisolone aceponate itself binds to the intracellular glucocorticoid receptor and this is especially true for the principal metabolite 6α-methylprednisolone-17-propionate, which is formed after cleavage of the ester in the skin.
The steroid receptor complex binds to certain regions of DNA, thereby triggering a series of biological effects.
Binding of the steroid receptor complex results in induction of macrocortin synthesis. Macrocortin inhibits the release of arachidonic acid and thus the formation of inflammatory mediators such as prostaglandins and leukotrienes.
The immunosuppressive action of glucocorticoids can be explained by inhibition of cytokine synthesis and an antimitotic effect, which so far is not well understood.
Inhibition of the synthesis of vasodilating prostaglandins or potentiation of the vasoconstrictive effect of adrenaline finally results in the vasoconstrictive activity of glucocorticosteroids.
Pharmacokinetics: Methylprednisolone aceponate becomes available from the formulation base. The concentration in the stratum corneum and living skin decreases from the outside to the inside.
Methylprednisolone aceponate is hydrolized in the epidermis and dermis to the main metabolite 6α-methylprednisolone-17-propionate which binds more firmly to the corticoid receptor than the parent drug, an indication of a bioactivation in the skin. The rate and extent of percutaneous absorption of a topical corticoid depends on a series of factors: chemical structure of the compound, the composition of the vehicle, the concentration of the compound in the vehicle, the conditions of exposure (area treated, duration of exposure, open or occlusion) and the skin status (kind and severity of skin disease, anatomical site etc.).
Percutaneous absorption of methylprednisolone aceponate from the cream, ointment and fatty ointment formulations has been investigated in healthy volunteers. The percutaneous absorption after open application of the Methylprednisolone aceponate (Advantan) fatty ointment (2 x 20 g daily) for 5 days was estimated to 0.34% corresponding to a corticoid load of approximately 2 µg/kg/day. The respective figures after open application of the Methylprednisolone aceponate (Advantan) ointment (2 x 20 g daily) for 8 days were 0.65% (absorption) or 4 µg/kg/day (load). Under occlusive conditions the daily application of 2 x 20 g Methylprednisolone aceponate (Advantan) cream for 8 days led to a mean percutaneous absorption of ca. 3 % corresponding to a systemic corticoid load of ca. 20 µg/kg/day. The percutaneous absorption of methylprednisolone aceponate through skin pre-damaged by removal of the stratum corneum resulted in distinctly higher absorption (13-27% of the dose). In adult psoriatic and atopic patients, percutaneous absorption of methylprednisolone aceponate from the fatty ointment was about 2.5%. In three atopic children (9-10 years of age), percutaneous absorption of methylprednisolone aceponate from the fatty ointment was about 0.5-2% and thus not higher than that compared to adults.
After reaching the systemic circulation, the primary hydrolysis product of methylprednisolone aceponate, 6α-methyl-prednisolone-17-propionate is quickly conjugated with glucuronic acid and as a result, inactivated. The metabolites of methylprednisolone aceponate (main metabolite: 6α-methyl prednisolone-17-propionate-21-glucuronide) are eliminated primarily via the kidneys with a half-life of about 16 hours. Following i.v. administration, excretion with the urine and feces was complete within 7 days. No accumulation of drug substance or metabolites takes place in the body.
Toxicology: Preclinical safety data: In systemic tolerance studies following repeated subcutaneous and dermal administration methylprednisolone aceponate showed the action profile of a typical glucocorticoid. It can be concluded from these results that following therapeutic use of Methylprednisolone aceponate (Advantan) cream, ointment and fatty ointment no side-effects other than those typical of glucocorticoids are to be expected even under extreme conditions such as application over a large surface and/or occlusion.
Embryotoxicity studies with Methylprednisolone aceponate (Advantan) cream, ointment and fatty ointment led to results typical for glucocorticoids, i.e. embryolethal and/or teratogenic effects are induced in the appropriate test system. In view of these findings, particular care should be taken when prescribing Methylprednisolone aceponate (Advantan) cream, ointment and fatty ointment during pregnancy. The results of epidemiological studies are summarized under “Use in Pregnancy & Lactation”.
Neither in vitro investigations for detection of gene mutations on bacteria and mammalian cells nor in vitro and in vivo investigations for detection of chromosome and gene mutations gave any indication of a genotoxic potential of methylprednisolone aceponate.
Specific tumorigenicity studies using methylprednisolone aceponate have not been carried out.
Knowledge concerning the structure, the pharmacological effect mechanism and the results from systemic tolerance studies with long-term administration do not indicate any increase in the risk of tumor occurrence. As systemically effective immunosuppressive exposure is not reached with dermal application of Methylprednisolone aceponate (Advantan) cream, ointment and fatty ointment under the recommended conditions of use, no influence on the occurrence of tumors is to be expected.
In investigations of the local tolerance of methylprednisolone aceponate and Methylprednisolone aceponate (Advantan) formulations on the skin and the mucosa no findings other than the topical side-effects known for glucocorticoids were recorded.
Methylprednisolone aceponate showed no sensitizing potential on the skin of the guinea-pig.
In general, the duration of use should not exceed 12 weeks in adults and 4 weeks in children.
Pediatric population: Dose adjustments are not required when Methylprednisolone aceponate (Advantan) cream is administered to children aged 3 years or older and adolescents. In general, the duration of use should not exceed 4 weeks in children. The safety of Methylprednisolone aceponate (Advantan) cream in children below the age of 3 years has not been established. No data are available.
Dose adjustments are not required when Methylprednisolone aceponate (Advantan) ointment and Methylprednisolone aceponate (Advantan) fatty ointment are administered to infants, children, and adolescents. In general, the duration of use should not exceed 4 weeks in children.
Hypersensitivity to the active substance or to any of the excipients.
If the skin dries out excessively under protracted use of Methylprednisolone aceponate (Advantan) cream, a switch should be made to one of the formulations with a higher fat content (Methylprednisolone aceponate (Advantan) ointment or Methylprednisolone aceponate (Advantan) fatty ointment).
Care must be taken when using Methylprednisolone aceponate (Advantan) cream, ointment or fatty ointment to avoid contact with the eyes, deep open wounds and mucosae.
No impairment of the adrenocortical function has been observed in children on large area (40-90 % of the skin surface) nonocclusive treatment with Methylprednisolone aceponate (Advantan) 0.1% fatty ointment. After application of Methylprednisolone aceponate (Advantan) 0.1% ointment to 60 % skin surface area under occlusive conditions for 22 hours, suppression of plasma cortisol levels and influence on circadian rhythm was observed in adult healthy volunteers.
Extensive application of topical corticosteroids to large areas of the body or for prolonged periods of time, in particular under occlusion, significantly increases the risk of systemic side effects. Note that diapers can be occlusive. This is especially relevant as Methylprednisolone aceponate (Advantan) cream is also not recommended for use in children under 3 years of age.
As known from systemic corticoids, glaucoma may also develop from using local corticoids (e.g. after large-dosed or extensive application over a prolonged period, occlusive dressing techniques, or application to the skin around the eyes).
Two excipients contained in Methylprednisolone aceponate (Advantan) 0.1% cream (cetostearyl alcohol and butyl hydroxytoluene) may cause local skin reactions (e.g., contact dermatitis). Butyl hydroxytoluene may also cause irritation in the eyes and mucous membranes.
Effects on ability to drive or use machines: No influence on the ability to drive and use machines.
Animal experimental studies with methylprednisolone aceponate have shown embryotoxic and/or teratogenic effects. In general, the use of topical preparations containing corticoids should be avoided during the first trimester of pregnancy. In particular, treating large areas, prolonged use or occlusive dressings should be avoided during pregnancy.
Epidemiological studies suggest that there could possibly be an increased risk of oral clefts among newborns of women who were treated with glucocorticosteroids during the first trimester of pregnancy. The clinical indication for treatment must be carefully reviewed and the benefits weighed against the risks in pregnant women.
Lactation: In rats methylprednisolone aceponate showed practically no transfer to the neonates via the milk. But it is not known if methylprednisolone aceponate is secreted in human milk as systemically administered corticosteroids have been reported to appear in human milk. It is not known whether topical administration could result in sufficient systemic absorption of methylprednisolone aceponate to produce detectable quantities in human milk. Therefore caution should be exercised when administered to a nursing woman.
Nursing mothers should not be treated on the breasts. Treating large areas, prolonged use or occlusive dressings should be avoided during lactation.
Frequencies of side-effects observed in clinical studies and given in the tables as follows are defined according to the MedDRA frequency convention: very common (>1/10); common (>1/100, <1/10); uncommon (>1/1,000; <1/100), rare (>1/10,000, <1/1,000); very rare (<1/10,000), not known (cannot be estimated from available data). MedDRA version 12.0 was used for coding.
Methylprednisolone aceponate (Advantan) Cream 0.1%: See Table 1.
Methylprednisolone aceponate (Advantan) Ointment 0.1%: See Table 2.
Methylprednisolone aceponate (Advantan) Fatty Ointment 0.1%: See Table 3.
As with other corticoids for topical application, the following local side-effects may occur: skin atrophy, skin striae, application site folliculitis, hypertrichosis, telangiectasia, perioral dermatitis, skin discoloration, and allergic skin reactions to any of the ingredients of the formulations. Systemic effects due to absorption may occur when topical preparations containing corticoids are applied.